Immunomedics (NASDAQ:IMMU) has shown a rise of 24.7% or 5,071,300 shares in the short positions. The bets have increased to 25,569,090 shares on June 15,2016 from 20,497,790 shares on May 31,2016. With respect to the floated shares, the shorts are 29%. The days to cover are calculated to be 5, using the standard per day volume of 4,832,893 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Immunomedics (NASDAQ:IMMU): The stock opened at $2.36 on Friday but the bulls could not build on the opening and the stock topped out at $2.46 for the day. The stock traded down to $2.10 during the day, due to lack of any buying support eventually closed down at $2.17 with a loss of -13.20% for the day. The stock had closed at $2.50 on the previous day. The total traded volume was 13,369,548 shares.
The company shares have dropped -43.64% from its 1 Year high price. On Jun 2, 2016, the shares registered one year high at $5.44 and the one year low was seen on Sep 29, 2015. The 50-Day Moving Average price is $3.66 and the 200 Day Moving Average price is recorded at $2.85.
Immunomedics (NASDAQ:IMMU) has tumbled 16.86% during the past week and has dropped 53.03% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 15.48%. Immunomedics (NASDAQ:IMMU) has underperformed the index by 51.61% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Companys technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.